

Gary Wilcox is Chairman, CEO and a founder of Cocrystal Discovery, an antiviral drug discovery company. From 1993-2007, he was Executive Vice President of Operations and a member of the board of directors of Icos Corporation, where he played a key role in the development of Cialis. In 1982 Gary co-founded Ingene Inc., serving as its Chairman, President and CEO through private financings, an IPO and a successful merger with XOMA Corporation in 1989. Ingene developed fundamental gene expression technologies and antibodies patents, including the first chimeric anti-CD20 antibody patent which was licensed to Genentech for Rituxin. From 1974 until 1984, he was a Professor of Microbiology and a member of the Molecular Biology Institute at UCLA. He was the recipient of the American Cancer Society Faculty Research Award in 1977 for his pioneering work in positive control of gene expression. Gary has served on the Board of Directors of NASDAQ, New York and London stock exchange companies, as well as several private technology companies. He is the author of 72 scientific papers and holds 15 patents. Gary received his Ph.D in molecular biology and biochemistry from the University of California, Santa Barbara.